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TPFPatients and methods: LAHNC patients were treated with 4 courses of docetaxel/cisplatin/5-
fluorouracil (TPF) followed by randomization to either cisplatin 100 mg/m2 with conventional
radiotherapy (cis100 þ RT) or cisplatin 40 mg/m2 weekly with accelerated radiotherapy
(cis40 þ ART). Primary endpoint was feasibility, defined as receiving 90% of the scheduled
total radiation dose. Based on power analysis 70 patients were needed.
Results: 65 patients were enrolled. The data safety monitoring board advised to prematurely
terminate the study, because only 22% and 41% (32% in total) of the patients treated with
cis100 þ RT (n Z 27) and cis40 þ ART (n Z 29) could receive the planned dose cisplatin
during CRT, respectively, even though the primary endpoint was reached. Most common
grade 3e4 toxicity was febrile neutropenia (18%) during TPF and dehydration (26% vs
14%), dysphagia (26% vs 24%) and mucositis (22% vs 57%) during cis100 þ RT and
cis40 þ ART, respectively. For the patients treated with cis100 þ RT and cis40 þ ART,
two years progression free survival and overall survival were 70% and 78% versus 72% and
79%, respectively.
Conclusion: After TPF induction chemotherapy, cisplatin-containing CRT is not feasible in
LAHNC patients, because the total planned cisplatin dose could only be administered in
32% of the patients due to toxicity. However, all but 2 patients received more than 90% of
the planned radiotherapy.
Clinical Trials Information: NCT00774319.
ª 2015 Elsevier Ltd. All rights reserved.1. Introduction
Most locally advanced head and neck cancer (LAHNC)
patients are treated with concomitant chemo-
radiotherapy, since it has been shown that 5-years sur-
vival increased with 6e8% as compared to radiotherapy
alone [1]. The most common used schedule is the RTOG
schedule with cisplatin 100 mg/m2 on days 1, 22 and 43
combined with conventional radiotherapy [2].Alterna-
tively cisplatin 40 mg/m2 combined with conventional or
accelerated radiotherapy is applied [3e5]. A direct
comparison of these two schedules with respect to
toxicity, feasibility, or efficacy has not been performed
yet.
Induction chemotherapy (IC) may improve the
prognosis of LAHNC. Docetaxel, cisplatin and fluoro-
uracil (TPF) has been proven superior to cisplatin and
fluorouracil (PF) as induction chemotherapy in
LAHNC with regard to efficacy and toxicity in two
phase III studies, followed by radiotherapy alone, or by
radiotherapy and concurrent carboplatin [6,7]. The main
criticism on these phase III studies is their omission to
use standard concomitant cisplatin-based chemo-
radiotherapy after TPF. Before the start of our study,
no data were available on the feasibility of cisplatin-
containing TPF followed by cisplatin-based concomi-
tant chemoradiotherapy. We conducted a randomized
phase II study in which all LAHNC patients received
TPF followed by randomization to either concomitant
chemoradiotherapy with cisplatin 100 mg/m2 once every
3 weeks with conventional radiotherapy (cis100 þ RT)
or chemoradiotherapy with weekly cisplatin 40 mg/m2
and accelerated radiotherapy (cis40 þ ART). The aim ofthis CONDOR study was to evaluate the feasibility of
these schedules.
2. Patients and methods
2.1. Patients eligibility
Patients with pathologically proven non-metastatic,
previously untreated, locally advanced squamous cell
carcinoma of the oral cavity, oropharynx, hypopharynx
or larynx, stage III or IV, were eligible. Patients were
between 18 and 65 years of age, had a WHO perfor-
mance status of 0e1, adequate bone marrow, hepatic
and renal function. Exclusion criteria were active
alcohol addiction, admission for chronic obstructive
pulmonary disease during the last 12 months, weight
loss of more than 10% during the last 3 months prior to
study entry.
The ethics committee of the participating centers
approved the protocol and the study was conducted in
accordance with the Declaration of Helsinki. All pa-
tients provided written informed consent.
2.2. Treatment
The TPF regimen was the same regimen as used in the
EORTC 24971/TAX 323 study [7]. TPF was adminis-
tered via a central venous catheter on an inpatient basis
for the first two days. Thereafter the patients received
the last 3 days of 5-FU using a medication cassette
reservoir at home. After two cycles, radiological evalu-
ation according to RECIST version 1.0 was performed.
In case of complete response (CR), partial response (PR)
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and received another two cycles of TPF. Otherwise they
were randomized and started concomitant CRT.
All patients started concomitant chemoradiotherapy
between 3 and 6 weeks after the last cycle of TPF.
Intensity-modulated radiation therapy (IMRT) tech-
nique was mandatory. Dose to gross tumor volume was
70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23
fractions. Patients randomized to cis100 þ RT received
cisplatin 100 mg/m2 on days 1, 22 and 43 combined with
conventional radiotherapy 5 fractions per week with a
total treatment time of 7 weeks. Patients randomized to
cis40 þ ART received weekly cisplatin 40 mg/m2 for 6
cycles and accelerated radiotherapy of 6 fractions per
week, with a total treatment time of 6 weeks. On one day
of each week two fractions were delivered with an in-
terval of at least 6 h.
Carboplatin AUC 1.5 weekly was given instead of
cisplatin in case of MDRD <60 ml/min or ototoxicity
grade 3 or 4. In case of neutrophils <1.5  109/l or
platelets <100  109 cisplatin was interrupted for one
week or skipped in case of weekly cisplatin. Neck dissec-
tion was considered for patients with residual tumor.
2.3. Assessments
Adverse events were scored according to the NCIC-
CTG Common Toxicity Criteria version 3.0. Late ra-
diation toxicity in the follow-up was scored according to
RTOG/EORTC criteria. Weight was assessed before the
start of each cycle. In case of more than 10% weight loss
or aspiration a feeding tube was placed.
Tumor evaluation was performed after 2 cycles of
TPF, at the end of induction chemotherapy and 12
weeks after the end of chemoradiotherapy.
HPV status was determined with p16 immunohisto-
chemistry and PCR [8].
Quality of life questionnaires (EORTC QLQ-C30 and
EORTC H&N53) were assessed and audiometry was
performed at different time points (will be published
separately).
Interim analysis by a data safety monitoring board
(DSMB) was planned after treatment of 30 patients.
Except for the primary endpoint, no stopping rules were
defined.
2.4. Statistical analysis
Primary endpoint was feasibility of the treatment
schedules. All patients were classified according to
whether or not they completed the treatment based on
receiving at least 90% of the scheduled total radiation
dose. The secondary end points were toxicity, tumor
response, progression free survival (PFS), overall sur-
vival (OS) and quality of life.
Based on a previous study in which 80% of the pa-
tients received 100% of the total radiation dose, weexpected that 90% of the patients in our trial would
receive at least 90% of the radiation dose. If 32 of the 35
patients in each arm completed treatment, we could
conclude with 95% certainty that treatment was feasible
in at least 80% of the patients. Therefore, a total of 70
patients were needed.
Time to progression was calculated from the date of
treatment start to the date of the first tumor progression.
Overall survival was determined by measuring the time
from the start of treatment to the date of death. Cu-
mulative survival data were calculated using the
KaplaneMeier method. Feasibility was assessed by
intention-to treat as defined as the population of all
randomized patients analyzed in the arm they were
assigned by randomization.3. Results
3.1. Patients and treatment
Between December 2008 and February 2012 65 patients
from three centers in the Netherlands were included. Of
the 65 registered patients, 62 were assessable; two pa-
tients were excluded due to ineligibility and one patient
withdrew consent (Fig. 1). Baseline demographic and
clinical characteristics are shown in Table 1. HPV status
was positive in 13 patients, negative in 15 and unknown
in 11 oropharyngeal cancer patients.
Sixty-two patients started with induction chemo-
therapy, 47 patients (75.8%) received four cycles of TPF.
Four patients (6.5%) received only 3 cycles because of
toxicity. Eight patients (12.9%) received only two cycles
of TPF, of whom five patients because they did not show
any response and three patients were treated off proto-
col due to rapid PD (nZ 2) and poor clinical condition
due to toxicity (nZ 1). Three patients only received one
TPF; one patient died after 1 TPF, one patient had an
infective arthritis and was treated off protocol and one
patient developed renal insufficiency.
Therefore, 56 patients were randomized to concomi-
tant chemoradiotherapy, 27 patients to cis100 þ RT and
29 patients to cis40 þ RT. The mean RT dose in arm
cis100 þ RT was 68.3 Gy (SD 1,9) and in arm
cis40 þ ART 69.0 Gy (SD 1.7). In arm cis100 þ RT, 6
(22.2%) and 17 (63.0%) patients received three and two
cycles of cisplatin 100 mg/m2, respectively. Two patients
completed protocol with carboplatin instead of cisplatin
and two patients received one course cisplatin and two
courses carboplatin. In arm cis40 þ ART 12 patients
(41.4%) received all six planned cycles of cisplatin 40 mg/
m2, 8 (27.6%) patients received 5 cycles, 5 patients (18.5%)
4 cycles and 4 (13.8%) patients received only 3 cycles, of
whom 2 patients also received one course carboplatin.
The median dose cisplatin in both arms was 200 mg/m2.
The planned interim analysis after 30 randomized
patients showed that 35% of the patients received the
Fig. 1. CONSORT diagram.
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both arms. Therefore, the DSMB advised a second
interim analysis after 50 randomized patients. This
showed that only 32% of the patients received the
planned cisplatin dose in the concomitant chemo-
radiation part of the study. Consequently, although
almost all patients received at least 90% of the planned
radiotherapy, the DSMB recommended stopping
recruitment. At that moment 65 patients were registered
instead of the planned 70 patients.
3.2. Toxicity
Chemotherapy and acute radiotherapy toxicities are
listed in Table 2. Grade 3 or 4 neutropenic fever
occurred in 18% of patients during TPF, despiteprophylaxis with GCS-F. There was one treatment
related death after 1 TPF, probably due to a cardiac
event in a patient with a medical history of hyperten-
sion. During TPF there were 31 hospitalizations in 25
patients.
Ninety-six percent of the patients in arm cis100 þ RT
and 90% in arm cis40 þ ART experienced one or more
grade 3 toxicities, whereas grade 4 toxicity occurred in
15% versus 14% of the patients. Mucositis grade 3/4 was
seen in 26% versus 59% of the patients in arm cis100þRT
and arm cis40 þ ART, respectively (p < 0.05). The onset
of any grade mucositis was earlier in cis40þART than in
cis100 þ RT: during week 1e3 in 72% versus 40%,
respectively (pZ <0.05). In arm cis40 þ ART 5 patients
were hospitalized due to severe mucositis needing keta-
mine or sufentanil intravenously, versus nil in the
Table 1
Patient characteristics.
Total Z 62
pts N (%)
Cis100 þ RT Z
27 pts N (%)
Cis40 þ ART Z
29 pts N (%)
Sex
Male 50 (80.6) 17 (63) 27 (93.1)
Female 12 (19.4) 10 (37) 2 (6.9)
Age, years
Mean 53,4 54.0 53.2
Range 27e65 32e65 27e64
WHO performance status
0 49 (79) 23 (85.2) 23 (79.3)
1 13 (21) 4 (14.8) 6 (20.7)
Tumor site
Oral Cavity 12 (19.4) 4 (14.8) 6 (20.7)
Oropharynx 37 (59.7) 18 (66.7) 16 (55.2)
Hypopharynx 8 (12.9) 3 (11.1) 5 (17.2)
Larynx 5 (8.1) 2 (7.4) 2 (6.9)
T stage
T 1 4 (6.5) 0 3 (10.3)
T 2 7 (11.3) 5 (18.5) 2 (6.9)
T 3 22 (35.5) 8 (29.6) 12 (41.4)
T 4 29 (46.8) 14 (51.9) 12 (41.4)
N stage
N 0 14 (22.6) 5 (18.5) 8 (27.6)
N 1 3 (4.8) 2 (7.4) 1 (3.4)
N 2a 8 (12.9) 3 (11.1) 4 (13.8)
N 2b 22 (35.5) 9 (33.3) 10 (34.5)
N 2c 15 (24.2) 8 (29.6) 6 (20.6)
Disease stage
III 5 (8.1) 2 (7.4) 3 (10.3)
IV 57 (91.9) 25 (92.6) 26 (89.7)
HPV status OPC
Negative 15 (40.5) 5 (27.8) 9 (56.3)
Positive 13 (35.1) 7 (38.9) 5 (31.3)
Unknown 9 (24.3) 6 (33.3) 2 (12.5)
Abbreviations: pts: patients; Cis100 þ RT: cisplatinum 100 mg/m2
with conventional radiotherapy; Cis40 þ ART: cisplatinum 40 mg/m2
with accelerated radiotherapy; OPC: oropharyngeal cancer.
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tients with cisplatin 100 mg/m2 versus 14% in patients
treated with weekly cisplatin (p< 0.05). Main reasons for
delay or discontinuation of cisplatin were in arm
cis100 þ RT nephrotoxicity (n Z 7) and neutropenia
(n Z 5) and in arm cis40 þ ART thrombocytopenia
(nZ 7) and mucositis (nZ 3).
In arm cis100 þ RT 74% and in arm cis40 þ ART
90% of the patients needed a feeding tube, for median 10
versus 12 weeks, respectively (ns). During TPF most
patients gained weight with a median of 2 kg (SD 5.42).
During concomitant chemoradiotherapy patients lost
weight, median 5 kg (SD 4.14) and median 6 kg (SD
3.37) in arm cis100 þ RT and in arm cis40 þ ART,
respectively (ns). None of the patients needed parental
feeding.
3.3. Efficacy
After TPF four patients reached CR (6.5%), 34 PR
(54.8%), 14 SD with minor response (22.6%), 5 SD
without any response (8.1%) and two PD (3.2%); twopatients were not evaluable and 1 patient died after 1
TPF. The total response rate (CR þ PR) was 61.3%.
Twelve weeks after chemoradiotherapy, response rate
was 81.5% in arm cis100 þ RT and 72.4%, in arm
cis40 þ ART. Three patients in each arm were not
evaluable for response.
Elective neck dissections were performed in two of
the randomized patients, 1 in each arm. First relapses
occurred with local or regional disease site or both in
11%, 0% and 8% of the patients in arm cis100 þ RT and
in 10%, 10% and 10% in arm cis40 þ ART, respectively.
Distant metastases at first relapse were found in 2 pa-
tients in arm cis100 þ RT and in 1 patient in arm
cis40 þ ART.
After a median follow-up of 38 months, two years
PFS and OS for all 62 included patients were 65% and
72% respectively. For the randomized patients in arm
cis100 þ RT 2 years PFS and OS were 70% and 78% and
in arm cis40 þ ART 72% and 79% as shown in Fig. 2
(ns). Four patients developed a second primary tumor
in the follow-up. In oropharyngeal cancer patients 2
years OS was 80% in HPV negative and 92% in HPV
positive patients.
4. Discussion
Our study shows that induction chemotherapy with TPF
followed by cisplatin-based chemoradiotherapy is not
feasible, as only 22% of the patients treated with
cis100 þ RT and 41% of the patients treated with
cisplatin cis40 þ ART could receive the planned
cisplatin dose during chemoradiotherapy. The planned
radiotherapy could be given to 96% of the patients in
each arm. TPF IC was feasible since 76% of the patients
received all 4 planned cycles, whereas another 13% of
the patients discontinued after two not because of
toxicity.
Since there is no proven survival benefit of IC
compared to concomitant chemoradiotherapy, the latter
remains standard therapy in patients with LAHNC
[1,9,10]. Consequently, no concessions should be made
in the total dose of cisplatin during chemoradiotherapy
as we know that a cumulative dose of 200 mg/m2 is
needed for optimal antitumor activity [11,12]. In two
phase III studies investigating concomitant chemo-
radiotherapy with cisplatin 100 mg/m2 on days 1, 22, 43
70e85% of the patients received all planned cisplatin,
whereas  200 mg/m2 cisplatin could be administered in
approximately 90% of the patients [2,13].
In arm cis100 þ RT of our study only 85% received
200 mg/m2 cisplatin and 69% in arm cis40 þ ART. We
conclude that cisplatin-based CRT after IC with 4 cycles
of TPF is not feasible.
There have been more studies in which IC with TPF
has been studied. The TREMPLIN study investigated
TPF followed by CRT with cisplatin versus
Table 2
Chemotherapy and acute radiotherapy toxicity.
TPF (n Z 62)
(No. of patients)
Cis100 þ RT (n Z 27)
(No. of patients)
Cis40 þ ART (n Z 29)
(No. of patients)
All grade Grade 3 þ 4 All grade grade 3 þ 4 All grade Grade 3 þ 4
Local toxicity
Dysphagia 15 0 23 8 25 9
Dyspnea 4 0 4 2 2 1
Hair loss 45 0 14 0 13 0
Hearing loss 11 1 15 2 8 2
Mucositis 33 2 24 7 25 17
Pain 13 0 16 2 18 2
Stridor 0 0 1 1 0 0
Taste alteration 19 0 16 0 19 0
Tinitus 9 0 8 1 7 0
Xerostomia 1 0 14 0 10 0
General toxicity
Anorexia 28 4 13 2 20 9
Constipation 30 0 11 0 16 1
Coronary spasms 1 1 0 0 0 0
Creatinine increase 4 2 17 5 7 1
Deep vein thrombosis 2 2 0 0 0 0
Dehydration 8 6 11 7 6 4
Diarrhea 32 7 6 0 6 0
Edema 27 0 11 0 8 0
Fatigue 49 4 23 3 29 3
Infection 20 3 9 5 12 4
Nausea 44 3 21 5 23 4
Sensory neuropathy 23 0 23 4 20 1
Pneumonia 2 0 2 2 1 1
Vomiting 18 2 14 3 18 3
Weight loss 15 0 9 0 15 0
Hematological toxicity
Febrile neutropenia 11 11 2 2 2 2
Leukopenia 8 3 10 5 6 3
Neutropenia 6 4 8 3 4 1
Trombocytopenia 3 0 3 2 7 2
Abbreviations:TPF: docetaxel/cisplatin/5-fluorouracil; Cis100 þ RT: cisplatinum 100 mg/m2 with conventional radiotherapy.
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study, 47% of patients received the planned three cycles
of TPF with a dropout rate after TPF of 24%. Of the 58
patients starting chemoradiotherapy with cisplatin
100 mg/m2 only 42% completed full treatment. In both
this and our study only approximately 30e40% of the
patients received all planned cisplatin during chemo-
radiotherapy. The dropout rate after TPF in the
TREMPLIN study however, was high (24% vs 10% in
our study). Despite their observations, the investigators
still concluded that this treatment schedule was feasible.
Another study reported on a retrospective analysis of
TPF followed by chemoradiotherapy with cisplatin
100 mg/m2 [15]. In that trial, only two to three courses of
less-intense TPF (only 4 days of 5-fluorouracil) were
planned and only 87% of the 66 patients received 3
courses. Nine patients (14%) received no CRT after
TPF. Of the 59 patients receiving CRT, only 5%
received all planned 3 cycles of cisplatin and only 66% of
the patients could receive 200 mg/m2 cisplatin. Grade 3
skin toxicity or mucositis occurred in 73% and 85% of
the patients and there was a high rate of unplannedhospital admissions. Nevertheless, the authors stated
that this schedule was feasible.
Likewise, high toxicity rates were found in our study.
Main differences between the two treatment arms were a
high rate of renal toxicity in patients receiving cisplatin
100 mg/m2 with conventional radiotherapy and a high
rate of mucositis in the patients who received weekly
cisplatin 40 mg/m2 with accelerated radiotherapy. The
high rate of mucositis is probably caused by the accel-
erated radiotherapy, as described earlier [5,16].
In our study we chose to treat patients with four
courses of TPF, according to the TAX 323 regimen,
which seemed less toxic than the schedule used in the
TAX 324 [6,7]. After TPF we decided to use the stan-
dard RTOG schedule of conventional radiotherapy with
cisplatin 100 mg/m2 versus accelerated radiotherapy
with weekly cisplatin 40 mg/m2. Accelerated radio-
therapy was selected because of the better local regional
control over conventional radiotherapy, albeit without
any benefit in overall survival [17,18].
We found a 2 years OS of 70% in our total popula-
tion and 76% in the intention-to-treat population. This
Fig. 2. KaplaneMeier survival plots for progression free survival (A), overall survival (B), loco regional failure (C) and distant failure (D)
between the treatment arms.
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in other studies with IC and conventional chemo-
radiotherapy in LAHNC [2,6,7,10,13]. In the PARA-
DIGM and DeCIDE trials, developed to compare IC
directly with chemoradiotherapy, overall survival at 3
years were 70e78% [9,10]. The high survival rates, even
in the control arms, of these recent studies compared to
earlier trials, may be, partly, explained by HPV status.
Patients with HPV positive oropharyngeal cancers have
better survival rates compared to HPV negative tumors
[19]. Although HPV status was not determined in the
PARADIGM and DeCIDE study, more than half of the
included patients presented with primary tumors in the
oropharynx. We found HPV positivity in half of the
patients with oropharyngeal carcinoma.
In conclusion, based on our data we do not recom-
mend TPF induction chemotherapy followed by
cisplatin-based chemoradiotherapy in routine clinicaldaily practice, for non-organpreservation. Still, in
exceptional cases, for example in patients with N3 stages
with collapse, or with cranial nerve involvement, or
when rapid response is mandatory, and organ-
preservation, it can be considered to give one or two
courses TPF induction, followed by concomitant
chemoradiotherapy.
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